Abscess incision and drainage (I&D) is a common urgent care procedure and is the primary treatment for most uncomplicated cutaneous abscesses. Successful outpatient care depends less on prescribing antibiotics than on correctly identifying a drainable collection, achieving adequate evacuation and disruption of loculations, recognizing high-risk anatomy or deep infection, and arranging appropriate reassessment. This guide addresses routine superficial skin abscess management; clinicians should independently verify current institutional protocols, medication dosing, product labeling, local antibiograms, and referral pathways before clinical use.

Clinical overview

A cutaneous abscess is a localized collection of pus in the dermis or subcutaneous tissue. It commonly presents as a painful, tender, erythematous, fluctuant nodule, sometimes with a central pustule or spontaneous drainage. Staphylococcus aureus, including community-associated methicillin-resistant S. aureus (MRSA), is a frequent cause. Purulent lesions described by patients as “spider bites” should prompt consideration of staphylococcal infection, including MRSA. [1,2]

For a drainable abscess, I&D is the essential intervention. Antibiotics may improve outcomes for selected patients after drainage, but they do not replace drainage when a meaningful purulent collection is present. [1,3,4]

Clinical significance, etiology, and risk factors

Abscess formation follows inoculation of bacteria through disrupted skin, hair follicles, minor trauma, shaving, friction, injection drug use, or preexisting dermatoses. Pus accumulates in a cavity that is relatively poorly penetrated by systemic antibiotics; source control is therefore critical. Furuncles arise from infected hair follicles, while carbuncles are deeper coalescent infections of contiguous follicles. Inflamed epidermoid cysts may mimic abscesses but can contain keratinous material and may be predominantly inflammatory rather than infectious. [1]

Important risk factors include prior MRSA infection or colonization, close-contact living environments, contact sports, diabetes, obesity, tobacco use, hidradenitis suppurativa, chronic skin disease, immunosuppression, injection drug use, recent surgery, and retained foreign material. Recurrent lesions in the axillae, groin, inframammary folds, or buttocks should raise concern for hidradenitis suppurativa. A recurrent abscess at one specific site warrants assessment for a cyst, sinus tract, pilonidal disease, foreign body, or other local anatomic cause. [1]

Focused history

• Onset, progression, spontaneous drainage, prior episodes, and preceding trauma, shaving, bite, injection, procedure, or surgery.
• Fever, rigors, malaise, rapidly progressive pain, vomiting, confusion, or other systemic symptoms.
• Location-specific symptoms: pain with eye movement or vision change; dental pain; dysphagia; rectal pain; urinary symptoms; breast symptoms; joint pain or restricted motion; genital pain or swelling.
• Diabetes, renal or hepatic disease, immune compromise, chemotherapy, chronic corticosteroid use, neutropenia, HIV, anticoagulant or antiplatelet therapy, and prosthetic material.
• Pregnancy or possibility of pregnancy; breastfeeding status.
• Medication allergies, prior antimicrobial adverse events, current medications that increase risk of hyperkalemia or bleeding, and prior culture results.
• MRSA history in the patient or household, recurrent infections, and barriers to 24- to 48-hour follow-up.

Focused examination

Record complete vital signs before the procedure. Examine the lesion for size, fluctuance, induration, pointing, central necrosis, active drainage, surrounding erythema, lymphangitis, bullae, crepitus, skin anesthesia, and pain out of proportion to examination. Measure and document the area of erythema and the suspected abscess dimensions. Assess distal neurovascular status and active range of motion when lesions involve an extremity or lie near a joint, tendon, or neurovascular bundle.

Examine regional lymph nodes when clinically relevant. Do not anchor on “abscess” when the lesion is unusually painful, fixed, pulsatile, ulcerated, recurrent at an atypical site, associated with a deep mass, or accompanied by disproportionate systemic illness.

Differential diagnosis

• Cellulitis without drainable collection.
• Furuncle, carbuncle, infected epidermoid cyst, hidradenitis suppurativa, or pilonidal disease.
• Hematoma, seroma, inflamed lymph node, thrombosed superficial vein, bursitis, or foreign-body reaction.
• Herpes simplex, zoster, arthropod reaction, pyoderma gangrenosum, vasculitis, or malignancy.
• Septic bursitis, septic arthritis, flexor tenosynovitis, deep-space hand infection, odontogenic infection, perirectal abscess, or breast abscess.
• Necrotizing soft-tissue infection or myonecrosis.

Must-not-miss diagnoses and emergency transfer criteria

Do not attempt routine urgent care I&D when emergency department evaluation, surgical consultation, specialty management, advanced imaging, intravenous therapy, or procedural sedation may be needed. Transfer or arrange immediate higher-level evaluation for:

• Sepsis, hemodynamic instability, altered mental status, rapidly progressive infection, or inability to tolerate oral intake.
• Suspected necrotizing infection: pain out of proportion, rapidly advancing erythema or edema, bullae, skin necrosis, crepitus, anesthesia, systemic toxicity, or severe pain extending beyond visible skin findings.
• Concern for deep infection, pyomyositis, septic arthritis, osteomyelitis, septic bursitis requiring aspiration/operative management, flexor tenosynovitis, or deep-space hand infection.
• Periorbital or orbital symptoms, facial abscess near the eye or central face with concern for complex anatomy, dental/deep neck infection, airway symptoms, or floor-of-mouth swelling.
• Perirectal, perianal, genital, scrotal, vulvar, or suspected Bartholin abscess when clinician expertise, equipment, and follow-up are insufficient; any concern for Fournier gangrene requires emergency transfer.
• Large, deep, multiloculated, recurrent, postoperative, or anatomically high-risk abscesses; lesions adjacent to major vessels, nerves, tendons, prosthetic material, or joints.
• Pulsatile lesion, bruit, unexplained expanding mass, or concern for pseudoaneurysm; do not incise.
• Severe immunocompromise, febrile neutropenia, poorly controlled diabetes with systemic illness, or substantial inability to return for reassessment.
• Infants, uncooperative young children, or patients whose pain/anxiety cannot be safely managed with local anesthesia and the urgent care’s available resources.

Diagnostic approach and point-of-care ultrasound

History and examination may identify an obvious superficial collection. When fluctuance is absent, anatomy is uncertain, lesion depth is unclear, or cellulitis versus abscess will change management, point-of-care ultrasound (POCUS) is valuable. Typical abscess findings include a discrete hypoechoic or heterogeneous fluid collection, posterior acoustic enhancement, internal debris, and dynamic swirling of contents with compression. Cellulitis more often produces subcutaneous edema with “cobblestoning” and no organized fluid cavity.

POCUS should also assess collection size, depth, loculations, proximity to vessels or tendons, and whether a lesion is too deep for safe ambulatory drainage. A systematic review and meta-analysis found high diagnostic accuracy for POCUS in suspected skin and soft-tissue abscesses; it also changed management correctly in a meaningful minority of cases. [5] Ultrasound informs but does not replace clinical judgment, and it should not delay transfer when a dangerous infection is suspected.

Routine blood testing is generally unnecessary for a well-appearing patient with a simple superficial abscess. Obtain a wound culture when there is severe infection, recurrent infection, treatment failure, significant immune compromise, unusual exposure, substantial surrounding cellulitis, or concern that results will alter therapy. IDSA recommends culture of pus from abscesses and carbuncles, while recognizing that treatment without culture is reasonable in typical uncomplicated cases. [1]

Management principles

Determine whether the lesion is drainable, whether the patient is stable for outpatient care, and whether antibiotics are indicated in addition to source control. I&D is recommended for abscesses, large furuncles, carbuncles, and inflamed epidermoid cysts with a drainable component. [1]

Antibiotic decisions should be individualized. Traditional guidance emphasizes systemic signs, impaired host defenses, multiple lesions, extremes of age, failure of drainage alone, and extensive surrounding infection. More recent randomized trials found modestly higher cure rates after I&D when trimethoprim-sulfamethoxazole (TMP-SMX) or clindamycin was used compared with placebo in settings with prevalent MRSA. [3,4] This benefit must be balanced against adverse effects, allergy history, resistance patterns, drug interactions, pregnancy considerations, antimicrobial stewardship, and the likelihood of reliable follow-up.

Medication options, precautions, and counseling

Antibiotics are adjuncts, not substitutes for drainage. Select therapy using local susceptibility data and culture results when available. The following are common outpatient options for MRSA-suspected purulent infection after adequate drainage; they are examples, not universal regimens.

• TMP-SMX: For selected adults, a common regimen is one to two double-strength tablets (160 mg TMP/800 mg SMX per tablet) orally every 12 hours for 5 to 7 days; some trial regimens used 320 mg/1,600 mg every 12 hours for 7 days. [3] Pediatric treatment requires weight-based dosing expressed as the TMP component, maximum-dose limits, and independent verification. Avoid in infants younger than 2 months. Use caution or avoid with sulfonamide allergy, significant renal impairment without adjustment, hyperkalemia, folate deficiency, and pregnancy when safer alternatives are appropriate; avoid near term because of neonatal bilirubin concerns. Review interactions with warfarin, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, and other agents that increase potassium or creatinine.
• Clindamycin: A common adult regimen is 300 to 450 mg orally every 6 to 8 hours for 5 to 7 days. Pediatric dosing is weight-based and requires verification of the formulation, maximum dose, local susceptibility, and inducible resistance testing when culture data are available. Counsel regarding diarrhea and the risk of Clostridioides difficile infection; stop the medication and seek evaluation for severe or persistent diarrhea. Hepatic dysfunction may warrant closer monitoring or adjustment depending on severity and duration.
• Doxycycline: A common adult regimen is 100 mg orally every 12 hours for 5 to 7 days. It has MRSA activity in many communities but unreliable activity against group A streptococci; if clinically important nonpurulent cellulitis is also present, select or add streptococcal coverage according to local guidance. Avoid or use only after careful risk-benefit assessment during pregnancy; tetracycline labeling warns about fetal and dental/bone effects. Pediatric use, particularly in children younger than 8 years, should follow current pediatric guidance and individualized risk-benefit assessment. Counsel patients to take with water, remain upright to reduce esophagitis risk, and use sun protection because of photosensitivity. Separate from iron, calcium, magnesium, and antacids.
• Culture-directed beta-lactam therapy: If culture identifies methicillin-susceptible S. aureus or if management is directed at uncomplicated nonpurulent cellulitis without MRSA risk factors, an appropriate beta-lactam may be used according to current guidelines and allergy history. A beta-lactam alone should not be presumed adequate for a purulent abscess in a community with substantial MRSA prevalence.

For pregnancy, lactation, pediatric patients, frail older adults, renal or hepatic impairment, anticoagulation, complex allergy histories, and polypharmacy, medication selection should be individualized. Verify dosing using current prescribing information and a reliable pediatric or renal dosing resource before prescribing.

Abscess incision and drainage procedure

Indications

Perform I&D for a clinically or sonographically confirmed superficial, accessible, drainable cutaneous abscess when the patient is stable, pain can be managed safely, nearby anatomy is understood, and outpatient follow-up is feasible.

Relative contraindications and reasons to defer

Defer routine urgent care drainage for the emergency-transfer conditions listed above; unclear diagnosis; suspected vascular lesion; deep or large collection; proximity to critical structures; need for procedural sedation beyond facility capability; uncontrolled bleeding risk; or inability to obtain informed consent or provide appropriate aftercare.

Preparation and equipment

• Personal protective equipment, procedure tray, antiseptic solution, sterile gauze, absorbent dressing, tape, specimen container and culture swab when indicated.
• Local anesthetic, syringe, needles, scalpel with an appropriate blade, hemostat or curved clamp, blunt probe, irrigation supplies, and optional packing material.
• POCUS with high-frequency linear probe and sterile barrier when available and indicated.
• Sharps container, wound-care instructions, and capability for reassessment of vital signs and neurovascular status.

Explain expected benefits, alternatives, and risks, including pain, bleeding, incomplete drainage, need for repeat drainage, scarring, recurrence, infection progression, damage to nearby structures, medication adverse effects, and need for emergency transfer. Obtain and document informed consent. Position the patient comfortably with adequate exposure, lighting, assistance, and safe access to the lesion.

Analgesia and anesthesia

Local anesthesia is often less effective in the acidic, inflamed abscess center. Use a field block through uninvolved surrounding skin when possible. Lidocaine 1% is commonly used; calculate the maximum dose from the patient’s weight and the specific product. A traditional maximum for plain lidocaine is 4.5 mg/kg, not to exceed 300 mg; when epinephrine-containing lidocaine is appropriate, the traditional maximum is 7 mg/kg, not to exceed 500 mg. These limits may not apply in every clinical context and should be reduced or reconsidered in frailty, severe hepatic impairment, low body weight, significant cardiac disease, or when other local anesthetics have been administered. Pediatric dosing must be weight-based and independently verified.

Oral analgesics before the procedure may be useful when not contraindicated. Consider the patient’s anticoagulant use, renal function, hepatic disease, pregnancy, substance use history, and drug interactions before selecting analgesics. Do not exceed the urgent care’s sedation capability.

Step-by-step technique

1. Confirm the target with examination and, when indicated, POCUS. Mark the area of surrounding erythema and identify the point of maximal fluctuance or sonographic collection.
2. Prepare the skin with antiseptic and allow adequate drying time. Drape as appropriate.
3. Administer a field block around, rather than directly into, the most inflamed tissue. Allow time for anesthetic effect.
4. Make a linear incision over the point of maximal fluctuance, generally along relaxed skin tension lines when feasible and with attention to anatomy and dependent drainage. The incision must be large enough to permit evacuation and instrument entry; a tiny stab incision may inadequately drain a loculated cavity.
5. Express purulent material. Obtain a culture from fresh pus before irrigation when culture is indicated.
6. Use a hemostat or blunt probe to gently explore the cavity and break loculations. Avoid deep blind dissection, especially near tendons, nerves, vessels, joints, breast tissue, facial structures, or genital/perirectal anatomy.
7. Irrigate if desired to remove debris. Ensure continued drainage and inspect for retained foreign material or keratinous cyst contents.
8. For most simple cutaneous abscesses, place an external absorbent dressing without routine cavity packing. Evidence has not shown clear outcome benefit from routine packing and suggests increased pain. Packing may still be selectively used for a large cavity, ongoing bleeding, or concern for premature skin closure, but practice varies. [1,6]
9. Apply dressing, reassess hemostasis, pain, distal neurovascular status when relevant, and repeat vital signs if initially abnormal or clinically indicated.

Aftercare, disposition, and follow-up

A clinically stable patient with an adequately drained superficial abscess, controlled pain, reliable follow-up, and no red flags may generally be discharged. Provide written instructions to keep the dressing clean and dry initially, change outer dressings when saturated, wash hands before and after wound care, avoid squeezing or probing the wound, and avoid sharing towels, razors, clothing, or athletic equipment. Encourage completion of prescribed antibiotics when used and review medication-specific adverse effects.

Arrange reassessment in 24 to 48 hours for packed wounds, large cavities, substantial surrounding inflammation, high-risk patients, uncertain adequacy of drainage, or patients with limited self-care capacity. Uncomplicated wounds without packing may require follow-up based on clinical judgment, but patients should have a clear path for prompt reassessment. Review final culture and susceptibility results, contact the patient when therapy should change, and document that communication.

Expected improvement is decreased pain and pressure within 24 to 48 hours; drainage may continue briefly. Induration and erythema can take longer to resolve. Lack of improvement may reflect residual loculations, inadequate incision size, incorrect diagnosis, resistant organism, deep infection, poor adherence, foreign body, or an underlying condition such as hidradenitis suppurativa.

Return and emergency precautions

• Fever, shaking chills, fainting, confusion, vomiting, or worsening generalized illness.
• Rapidly expanding redness, severe or escalating pain, red streaking, new bullae, skin discoloration, numbness, or crepitus.
• Persistent or worsening swelling, failure to drain, recurrent collection, uncontrolled bleeding, or inability to move a nearby joint or digit.
• New eye symptoms, facial swelling, breathing or swallowing difficulty, rectal/genital pain or swelling, or severe diarrhea after antibiotics.
• Allergic reaction symptoms including hives, facial swelling, wheeze, or trouble breathing.

Documentation considerations

• History, risk factors, pregnancy status when relevant, allergies, medications, comorbidities, vital signs, and absence or presence of systemic symptoms.
• Exact lesion location; dimensions; surrounding erythema measurements; fluctuance; drainage; neurovascular and range-of-motion findings when applicable.
• POCUS findings, including depth, dimensions, loculations, and nearby structures, if performed.
• Consent discussion, anesthetic agent/concentration/volume, technique, incision size, amount and character of drainage, probing/loculation disruption, irrigation, culture collection, packing or non-packing decision, dressing, complications, and patient tolerance.
• Antibiotic rationale, culture follow-up plan, discharge condition, follow-up interval, and specific return/emergency precautions.

Clinical takeaways

• Identify a drainable collection; antibiotics alone are inadequate source control for a clinically meaningful abscess.
• Use POCUS when the diagnosis, depth, anatomy, or procedural target is uncertain.
• Make an incision adequate for evacuation and carefully disrupt loculations; incomplete drainage is a common cause of failure.
• Reserve routine urgent care I&D for superficial, accessible lesions in stable patients with reliable follow-up.
• Use adjunctive antibiotics selectively, incorporating systemic findings, host factors, local MRSA resistance, culture data, medication safety, and patient values.
• Routine packing of simple cutaneous abscesses is usually unnecessary and may increase pain.

References

1. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296.
2. Centers for Disease Control and Prevention. Clinical overview of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare settings [Internet]. Atlanta (GA): CDC; 2025 Jun 27 [cited 2026 Aug 15].
3. Talan DA, Mower WR, Krishnadasan A, Abrahamian FM, Lovecchio F, Karras DJ, et al. Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016;374(9):823-832. doi:10.1056/NEJMoa1507476.
4. Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, et al. A placebo-controlled trial of antibiotics for smaller skin abscesses. N Engl J Med. 2017;376(26):2545-2555. doi:10.1056/NEJMoa1607033.
5. Gottlieb M, Avila J, Chottiner M, Peksa GD. Point-of-care ultrasonography for the diagnosis of skin and soft tissue abscesses: a systematic review and meta-analysis. Ann Emerg Med. 2020;76(1):67-77. doi:10.1016/j.annemergmed.2020.01.004.
6. Mohamedahmed AYY, Zaman S, Stonelake S, Ahmad AN, Datta U, Hajibandeh S, Hajibandeh S. Incision and drainage of cutaneous abscess with or without cavity packing: a systematic review, meta-analysis, and trial sequential analysis of randomised controlled trials. Langenbecks Arch Surg. 2021;406(4):981-991. doi:10.1007/s00423-020-01941-9.

Educational disclaimer: This article is intended for clinician education and does not replace individualized clinical judgment, supervision, consultation, local protocols, or current prescribing information. Medication selection and dosing, procedural suitability, pregnancy considerations, pediatric care, renal/hepatic adjustment, and emergency transfer decisions must be independently verified for each patient.